期刊文献+

醋氯芬酸缓释片在犬体内药代动力学及其相对生物利用度研究 被引量:4

Studies on Pharmacokinetics and Relative Bioavailability of Aceclofenac Controlled-Release Tablets in Dogs
下载PDF
导出
摘要 目的 :建立了测定犬血浆中醋氯芬酸浓度的HPLC方法 ,研究醋氯芬酸缓释片在犬体内药代动力学及其相对生物利用度。方法 :样品采用正己烷提取 ,HPLC UV法测定 ,紫外检测波长为 2 76nm。流动相 :甲醇 三蒸水 冰醋酸 (77∶2 3∶0 3)组成。流速 1 5ml/min。色谱柱为C18,10 μm ,柱长 30 0mm× 4 6mmI.D .。 结果 :血浆中杂质不干扰样品峰 ,方法的回收率大于 90 % ,最低检测浓度醋氯芬酸为 1 6 5 μg/ml;线性范围为 1 6 5~ 10 0μg/ml。犬单剂量ig 2 0 0mg醋氯芬酸缓释片后 ,估算的末端相半衰期为 6 0 3± 1 95h ,峰时间和峰浓度分别为 5 0± 2 7h和 6 1 36± 2 0 75 μg/ml,MRT为 9 79± 1 71h。其t1/ 2 、tmax、MRT显著大于普通片 (P <0 0 5 ) ,峰浓度显著低于普通片 (P <0 0 5 )。结论 :本文建立的HPLC UV法适合用于醋氯芬酸的临床研究 ;缓释片具有缓释特征 。 AIM:To establish a HPLC method for determination of aceclofenac in dog plasma and to study pharmacokinetics and bioavailability of aceclofenac controlled release tablets in dogs.METHOD:The plasma samples was extracted with n-hexane and determined by HPLC-UV(λ=276nm).Mobile phase was composed of methanol-water-acetic acid(77∶23∶0.3).The flow rate was 1 5 ml/min The column is C 18 ,10μm,300 mm×4 6 mm ID RESULT: The impurities didn't interfere the sample peak The assay exhibited a linear range of 1 65~100 μg/ml The absolute recovery of aceclofenac was larger than 90% After oral administration of a single dose,the pharmacokinetic parameters of aceclofenac were:t 1/2 6 03±1 95 h,t max 5 0±2 7 h,c max 61 36±20 75 μg/ml,MRT 9 79±1 71 h The aceclofenac controlled release tablet parameters of t 1/2 ,t max and MRT were significantly higher than common tablet(P<0 05) c max was lower than common tablet(P<0 05) CONCLUSION:The method of HPLC-UV established can be used for clinical study of aceclofenac The controlled-release tablets show controlled release profile and bioequivalence in absorption level to common tablets
出处 《中国药科大学学报》 CAS CSCD 北大核心 2004年第5期443-445,共3页 Journal of China Pharmaceutical University
关键词 醋氯芬酸 缓释片 药代动力学 相对生物利用度 Aceclofenac Controlled-release tablet Pharmacokinetics Relative bioavailability
  • 相关文献

参考文献3

  • 1González-Alvaro I,Carmona L,Díaz-González F,et al.Aceclofenac,a new nonsteroidal antiinflammatory drug,decreases the expression and function or some adhesion molecules on human neutrophils[J].J Rheumatol,1996,23(4):723.
  • 2Kornasoff D,Maisenbacher J,Bowdler J,et al.The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis[J].Rheumatol Int,1996,16(6):225.
  • 3Martín-Mola E,Gijón-Baos J,Ansoleaga JJ,et al.Aceclofenac in comparison to ketoprofen in the treatment of rheumatoid arthristis[J].Rheumatol Int,1995,15(3):111.

同被引文献19

  • 1Altman R, Asch E, Bloeh D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee [ J ], Arthritis Rheum, 1986,29 (8) : 1039 - 49.
  • 2Cryer B, Fetdman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivior of widely used non-steroidal anti-inflammatory drugs [ J ]. Am J Med, 1998,104:413 - 21.
  • 3Van Ryn J, Pairet M. Selective cyclooxygenase-2 inhibitors : pharmacology, clinical effects and therapeutic potential [ J ]. Exp Opin Invest Drugs,1997,6:609 - 14.
  • 4Legrand E. Aceclofenac in the management of inflammatory pain [ J ]. Expert Opin Pharmacother,2004,5 ( 6 ) : 1347 - 57.
  • 5Schattenkirchner M, Milachowski KA. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain [ J ]. Clin Rheumatol,2003,22 (2) : 127 - 35.
  • 6Brogden RN, Wiseman LR. Aceclofenac. A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management [ J ]. Drugs, 1996,52 ( 1 ) : 113 -24.
  • 7El-Saharty YS,Refaat M,El-Khateeb SZ.Stability-indicating spectrophotometric and densitometric methods for determination of aceclofenac[J].Drug Development and Industrial Pharmacy,2002,28(5):571-582.
  • 8Xu G,Sunada H.Influence of formulation change on drug release kineties from hydroxypropylmethylcellulose matrix tablets[J].Chem Pharm Bull,1995,43(3):483-487.
  • 9魏伟,张玲玲,徐叔云.新药的临床研究设计要求[M].徐叔云主编:临床药理学(第三版),北京:人民卫生出版社,2004:5-70.
  • 10BROGDEN RN,WISEMAN LR.Aceclofenac.A review of its pharmacodynamic properties and therapeutic potential in the treatment of rheumatic disorders and in pain management[J].Drugs,1996,52(1):113 -124.

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部